PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION

Alexandra H. Filipovich, Norma K.C. Ramsay, Phyllis Irene Warkentin, Philip B. Mcglave, Gideon Goldstein, John H. Kersey

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Ten consecutive patients undergoing transplantation of bone marrow from histocompatible siblings for treatment of haematological malignancy took part in a pilot study to test the safety of invitro treatment of donor bone marrow with monoclonal antibody OKT3. Three male and seven female patients aged 7-34 years received concentrated bone-marrow buffy-coat cells which had been incubated with OKT3 before infusion. In-vitro studies confirmed that almost all immunocompetent T lymphocytes in the bone-marrow samples were coated with OKT3 at the time of infusion. In vitro, neonatal rabbit complement inhibited the proliferation of bone-marrow T lymphocytes in samples preincubated with OKT3 to less than 4% of the mitogenic responses of the untreated bone marrow. In contrast, fresh autologous complement did not effectively lyse OKT3-treated bone-marrow cells. Infusion of OKT3-treated bone marrow was safely accomplished, and engraftment was achieved in all patients (mean 23 days). Nine of ten patients survived for more than 100 days after bone-marrow transplantation, but significant acute graft-versus-host disease (GvHD) requiring treatment with steroids developed in five of the ten. This finding suggests that further modifications for bone-marrow pretreatment will be needed to achieve effective prophylaxis against acute GvHD in histocompatible bone-marrow transplantation.

Original languageEnglish (US)
Pages (from-to)1266-1269
Number of pages4
JournalThe Lancet
Volume319
Issue number8284
DOIs
StatePublished - Jun 5 1982

Fingerprint

Muromonab-CD3
Graft vs Host Disease
Bone Marrow Transplantation
Bone Marrow
Tissue Donors
T-Lymphocytes
Glycocalyx
Hematologic Neoplasms
Bone Marrow Cells
Siblings
Therapeutics
Steroids
Rabbits
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION. / Filipovich, Alexandra H.; Ramsay, Norma K.C.; Warkentin, Phyllis Irene; Mcglave, Philip B.; Goldstein, Gideon; Kersey, John H.

In: The Lancet, Vol. 319, No. 8284, 05.06.1982, p. 1266-1269.

Research output: Contribution to journalArticle

Filipovich, Alexandra H. ; Ramsay, Norma K.C. ; Warkentin, Phyllis Irene ; Mcglave, Philip B. ; Goldstein, Gideon ; Kersey, John H. / PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION. In: The Lancet. 1982 ; Vol. 319, No. 8284. pp. 1266-1269.
@article{b8753f0628364e82ba439f461d3c6f0a,
title = "PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION",
abstract = "Ten consecutive patients undergoing transplantation of bone marrow from histocompatible siblings for treatment of haematological malignancy took part in a pilot study to test the safety of invitro treatment of donor bone marrow with monoclonal antibody OKT3. Three male and seven female patients aged 7-34 years received concentrated bone-marrow buffy-coat cells which had been incubated with OKT3 before infusion. In-vitro studies confirmed that almost all immunocompetent T lymphocytes in the bone-marrow samples were coated with OKT3 at the time of infusion. In vitro, neonatal rabbit complement inhibited the proliferation of bone-marrow T lymphocytes in samples preincubated with OKT3 to less than 4{\%} of the mitogenic responses of the untreated bone marrow. In contrast, fresh autologous complement did not effectively lyse OKT3-treated bone-marrow cells. Infusion of OKT3-treated bone marrow was safely accomplished, and engraftment was achieved in all patients (mean 23 days). Nine of ten patients survived for more than 100 days after bone-marrow transplantation, but significant acute graft-versus-host disease (GvHD) requiring treatment with steroids developed in five of the ten. This finding suggests that further modifications for bone-marrow pretreatment will be needed to achieve effective prophylaxis against acute GvHD in histocompatible bone-marrow transplantation.",
author = "Filipovich, {Alexandra H.} and Ramsay, {Norma K.C.} and Warkentin, {Phyllis Irene} and Mcglave, {Philip B.} and Gideon Goldstein and Kersey, {John H.}",
year = "1982",
month = "6",
day = "5",
doi = "10.1016/S0140-6736(82)92840-9",
language = "English (US)",
volume = "319",
pages = "1266--1269",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8284",

}

TY - JOUR

T1 - PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATION

AU - Filipovich, Alexandra H.

AU - Ramsay, Norma K.C.

AU - Warkentin, Phyllis Irene

AU - Mcglave, Philip B.

AU - Goldstein, Gideon

AU - Kersey, John H.

PY - 1982/6/5

Y1 - 1982/6/5

N2 - Ten consecutive patients undergoing transplantation of bone marrow from histocompatible siblings for treatment of haematological malignancy took part in a pilot study to test the safety of invitro treatment of donor bone marrow with monoclonal antibody OKT3. Three male and seven female patients aged 7-34 years received concentrated bone-marrow buffy-coat cells which had been incubated with OKT3 before infusion. In-vitro studies confirmed that almost all immunocompetent T lymphocytes in the bone-marrow samples were coated with OKT3 at the time of infusion. In vitro, neonatal rabbit complement inhibited the proliferation of bone-marrow T lymphocytes in samples preincubated with OKT3 to less than 4% of the mitogenic responses of the untreated bone marrow. In contrast, fresh autologous complement did not effectively lyse OKT3-treated bone-marrow cells. Infusion of OKT3-treated bone marrow was safely accomplished, and engraftment was achieved in all patients (mean 23 days). Nine of ten patients survived for more than 100 days after bone-marrow transplantation, but significant acute graft-versus-host disease (GvHD) requiring treatment with steroids developed in five of the ten. This finding suggests that further modifications for bone-marrow pretreatment will be needed to achieve effective prophylaxis against acute GvHD in histocompatible bone-marrow transplantation.

AB - Ten consecutive patients undergoing transplantation of bone marrow from histocompatible siblings for treatment of haematological malignancy took part in a pilot study to test the safety of invitro treatment of donor bone marrow with monoclonal antibody OKT3. Three male and seven female patients aged 7-34 years received concentrated bone-marrow buffy-coat cells which had been incubated with OKT3 before infusion. In-vitro studies confirmed that almost all immunocompetent T lymphocytes in the bone-marrow samples were coated with OKT3 at the time of infusion. In vitro, neonatal rabbit complement inhibited the proliferation of bone-marrow T lymphocytes in samples preincubated with OKT3 to less than 4% of the mitogenic responses of the untreated bone marrow. In contrast, fresh autologous complement did not effectively lyse OKT3-treated bone-marrow cells. Infusion of OKT3-treated bone marrow was safely accomplished, and engraftment was achieved in all patients (mean 23 days). Nine of ten patients survived for more than 100 days after bone-marrow transplantation, but significant acute graft-versus-host disease (GvHD) requiring treatment with steroids developed in five of the ten. This finding suggests that further modifications for bone-marrow pretreatment will be needed to achieve effective prophylaxis against acute GvHD in histocompatible bone-marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0020061303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020061303&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(82)92840-9

DO - 10.1016/S0140-6736(82)92840-9

M3 - Article

VL - 319

SP - 1266

EP - 1269

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8284

ER -